Interleukin-6 (IL-6) and interleukin-8 (IL-8) play important roles in the progression of triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC).
This is the first experiment to combine small molecules targeting these two signaling pathways to treat TNBC and PDAC cells.
